Article
Levetiracetam Modulates Brain Metabolic Networks and Transcriptomic Signatures in the 5XFAD Mouse Model of Alzheimer’s disease
2023-11-14
Abstract excerpt
<h4>ABSTRACT</h4> <h4>INTRODUCTION</h4> Subcritical epileptiform activity is associated with impaired cognitive function and is commonly seen in patients with Alzheimer’s disease (AD). The anti-convulsant, levetiracetam (LEV), is currently being evaluated in clinical trials for its ability to reduce epileptiform activity and improve cognitive function in AD. The purpose of the current study was to apply pharmaco...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- db74b0c3-6bc3-55c2-89c8-c14fe632f3e2
- DOI
- 10.1101/2023.11.10.566574
